El interés en corto de Teladoc Health da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Teladoc Health. Los datos de interés en corto se actualizan cada dos semanas.

Teladoc Health (NYSE:TDOC) Bolsa, Informe de interés en corto

Teladoc Health

Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.

Teladoc Health Inc

Canaccord Genuity analyst Richard Close maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy and lowers the price target from $14 to $12.

News

Price Target

Analyst Ratings

TDOC

Canaccord Genuity Maintains Buy on Teladoc Health, Lowers Price Target to $12

Goldman Sachs analyst David Roman maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy and lowers the price target from $13 to $10.

Goldman Sachs Maintains Buy on Teladoc Health, Lowers Price Target to $10

Stifel analyst David Grossman maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and lowers the price target from $9 to $8.

Stifel Maintains Hold on Teladoc Health, Lowers Price Target to $8

Evercore ISI Group analyst Elizabeth Anderson maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a In-Line and lowers the price target from $8 to $7.

Evercore ISI Group Maintains In-Line on Teladoc Health, Lowers Price Target to $7

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $11.34, a high estimate of $16.00, and a low estimate of $8.00. A decline of 5.03% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746100892_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Teladoc Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.75</td>
<td>$11.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$10.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Teladoc Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Teladoc Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Teladoc Health: A Closer Look</h2>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>Teladoc Health: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Teladoc Health's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -3.03%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Teladoc Health's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.23% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Teladoc Health's ROA excels beyond industry benchmarks, reaching -1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.06.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 8 Analyst Projections For Teladoc Health

Needham analyst Ryan MacDonald reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Teladoc Healthto Hold

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.34) by 44.12 percent. This is a 61.22 percent increase over losses of $(0.49) per share from the same period last year. The company reported quarterly sales of $629.40 million which beat the analyst consensus estimate of $619.29 million by 1.63 percent. This is a 2.59 percent decrease over sales of $646.13 million the same period last year.

Earnings

Earnings Beats

CORRECTION: Teladoc Health Q1 Adj. EPS $(0.19) Beats $(0.34) Estimate, Sales $629.40M Beat $619.29M Estimate

Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported financial results for the first quarter Wednesday after the bell. Here&#8217;s a rundown<a href="https://www.benzinga.com/pressreleases/25/04/g45116556/teladoc-health-reports-first-quarter-2025-results"> of the report</a>.
Q1 Earnings: Teladoc reported first-quarter revenue of $629.4 million, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $619.29 million, according to <a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The company reported a first-quarter loss of 53 cents per share, missing analyst estimates for a loss of 34 cents per share.
Total revenue was down 3% on a year-over-year basis. Revenue fell 4% year-over-year in the U.S., but International revenue grew 6% year-over-year. Here&#8217;s a breakdown of revenue by segment:
<ul>
<li>Integrated Care revenue: up 3% to $389.5 million</li>
</ul>
<ul>
<li>BetterHelp&nbsp;revenue: down 11% to $239.9 million</li>
</ul>
<ul>
<li>Access Fees revenue: down 6% to $525.7 million</li>
</ul>
<ul>
<li>Other revenue: up 16% to $103.6 million</li>
</ul>
Cash flow from operations totaled $15.9 million in the quarter. The company said capital expenditures and capitalized software development costs came in at&nbsp;$31.6 million. Teladoc ended the period with approximately $1.19 billion in cash and cash equivalents.
&#8220;We are pleased with the solid start to 2025. Consolidated revenue and adjusted EBITDA were towards the higher end of our&nbsp;first quarter&nbsp;guidance&nbsp;ranges, including our Integrated Care segment being above our ranges for both measures and BetterHelp segment results in the upper half of our ranges as well,&#8221; said&nbsp;Chuck Divita, CEO of Teladoc Health.
&#8220;We also continue to make progress towards strategic priorities aimed at driving sustainable performance, including advancing our position in virtual mental health.&#8221;
In connection with the earnings release, Teladoc also announced that it acquired virtual mental health therapy provider UpLift for $30 million in an <a href="https://www.benzinga.com/pressreleases/25/04/g45116095/teladoc-health-acquires-uplift-expanding-consumer-access-to-mental-health-care-services-through-co">all-cash transaction</a>. The deal also includes up to $15 million in additional contingent earnout consideration.
Guidance:&nbsp;Teladoc expects second-quarter revenue of $614 million to $633 million, and full-year revenue of $2.47 billion to $2.58 billion. Analysts are anticipating full-year revenue of $2.52 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
The company also lowered its full-year earnings outlook. Teladoc anticipates a 2025 loss of 90 cents to $1.40 per share, down from prior guidance for a loss of 50 cents to $1.10 per share. Analysts are forecasting a loss of 93 cents per share. 
Teladoc executives are currently discussing the quarter on a call with investors and analysts that got started at 4:30 p.m. ET
TDOC Price Action: <a href="https://www.benzinga.com/quote/TDOC" target="_blank" rel="noreferrer noopener">Teladoc shares</a> were down 5.42% in after-hours, trading at $6.80 at the time of publication on Wednesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45115442/sell-in-may-and-go-away-looks-outdated-as-mayjuly-data-signal-bullish-sp-500-seasonality">&#8216;Sell In May And Go Away&#8217; Looks Outdated As May–July Data Signal Bullish S&amp;P 500 Seasonality</a></li>
</ul>
Photo: courtesy of Teladoc Health.

Guidance

Health Care

After-Hours Center

Movers

Teladoc Health Stock Slides On Q1 Earnings As Company Cuts FY25 Guidance

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) lowers FY2025 GAAP EPS guidance from $(1.10)-$(0.50) to $(1.40)-$(0.90) vs $(0.93) analyst estimate. Affirms FY2025 sales outlook from $2.47 billion-$2.58 billion to $2.47 billion-$2.58 billion vs $2.52 billion estimate.

Teladoc Health Lowers FY2025 GAAP EPS Guidance from $(1.10)-$(0.50) to $(1.40)-$(0.90) vs $(0.93) Est; Affirms FY2025 Sales Guidance of $2.47B-$2.58B vs $2.52B Est

Teladoc Health acquired UpLift in an all-cash transaction for $30 million, with up to $15 million in additional contingent earnout consideration. UpLift's 2024 revenue was approximately $15 million. The transaction closed on April 30, 2025, and the results of UpLift will be included in the company's BetterHelp reporting segment going forward.
 &nbsp;

Teladoc Health Acquires UpLift In All-cash Transaction For $30M

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Teladoc Health will report an earnings per share (EPS) of $-0.37.
Teladoc Health bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.01, leading to a 13.56% drop in the share price on the subsequent day.
Here's a look at Teladoc Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.29</td>
<td>-0.27</td>
<td>-0.34</td>
<td>-0.46</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.28</td>
<td>-0.19</td>
<td>-0.28</td>
<td>-0.49</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-14.000000000000002%</td>
<td>2.0%</td>
<td>-9.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745949754_0.png" alt="eps graph" />
<h3>Teladoc Health Share Price Analysis</h3>
Shares of Teladoc Health were trading at $7.16 as of April 28. Over the last 52-week period, shares are down 42.78%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Insights Shared by Analysts on Teladoc Health</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Teladoc Health.
The consensus rating for Teladoc Health is Neutral, based on 8 analyst ratings. With an average one-year price target of $11.34, there's a potential 58.38% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Phreesia, Evolent Health and HealthStream, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Phreesia, with an average 1-year price target of $31.8, suggesting a potential 344.13% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Evolent Health, with an average 1-year price target of $13.75, suggesting a potential 92.04% upside.</li>
<li>Analysts currently favor an Neutral trajectory for HealthStream, with an average 1-year price target of $30.0, suggesting a potential 318.99% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
Within the peer analysis summary, vital metrics for Phreesia, Evolent Health and HealthStream are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teladoc Health</td>
<td>Neutral</td>
<td>-3.03%</td>
<td>$451.56M</td>
<td>-3.23%</td>
</tr>
<tr>
<td>Phreesia</td>
<td>Buy</td>
<td>15.45%</td>
<td>$76.11M</td>
<td>-2.46%</td>
</tr>
<tr>
<td>Evolent Health</td>
<td>Outperform</td>
<td>16.27%</td>
<td>$75.71M</td>
<td>-3.00%</td>
</tr>
<tr>
<td>HealthStream</td>
<td>Neutral</td>
<td>5.18%</td>
<td>$49.12M</td>
<td>1.37%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Teladoc Health ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages. It also has the lowest Return on Equity among its peers. The company with the highest Revenue Growth and Gross Profit has a Buy rating. The company with the highest Return on Equity has an Outperform rating.
<h3>Delving into Teladoc Health's Background</h3>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>Teladoc Health's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Teladoc Health's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -3.03% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Teladoc Health's net margin is impressive, surpassing industry averages. With a net margin of -7.56%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Teladoc Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.23%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Teladoc Health's ROA excels beyond industry benchmarks, reaching -1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.06.
<a href="https://www.benzinga.com/quote/TDOC/earnings">To track all earnings releases for Teladoc Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Teladoc Health

Citigroup analyst Daniel Grosslight maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and lowers the price target from $11 to $8.75.

Citigroup Maintains Neutral on Teladoc Health, Lowers Price Target to $8.75

Jefferies analyst Glen Santangelo maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and lowers the price target from $10 to $8.

Jefferies Maintains Hold on Teladoc Health, Lowers Price Target to $8

In the preceding three months, 8 analysts have released ratings for Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $12.25, a high estimate of $16.00, and a low estimate of $8.00. This current average represents a 1.53% decrease from the previous average price target of $12.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1744372878_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Teladoc Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Lowers &#x7C;Neutral &#x7C; $8.00&#x7C;$9.50 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $13.00&#x7C;$16.00 &#x7C; 
&#x7C;Jessica Tassan &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $12.00&#x7C;$13.00 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $16.00&#x7C;$14.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $13.50&#x7C;$11.50 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $11.50&#x7C;$10.50 &#x7C; 
&#x7C;Sean Dodge &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $12.00&#x7C;$11.00 &#x7C; 
&#x7C;Michael Wiederhorn &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $12.00&#x7C;$14.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Teladoc Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Teladoc Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Teladoc Health</h2>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>A Deep Dive into Teladoc Health's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, Teladoc Health faced challenges, resulting in a decline of approximately -3.03% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin excels beyond industry benchmarks, reaching -7.56%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Teladoc Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.23%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Teladoc Health's ROA excels beyond industry benchmarks, reaching -1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: Teladoc Health's debt-to-equity ratio is below the industry average at 1.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

B of A Securities analyst Allen Lutz maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and lowers the price target from $9.5 to $8.

B of A Securities Maintains Neutral on Teladoc Health, Lowers Price Target to $8

New features for members and customers include:
<ul>
<li>A premium subscription to <a href="https://www.bettersleep.com">BetterSleep</a>, the award-winning app that promotes sleep quality and well-being.</li>
<li>Access to a registered dietitian for 1:1 support, medical nutrition therapy and personalized nutrition planning.</li>
<li>Proactive outreach from expert health coaches for those at highest risk.</li>
<li>Convenient at-home testing for key cardiometabolic measures, including A1c and blood lipids.</li>
<li>Dynamic health insights that leverage patient-reported data and inputs from Teladoc Health's connected devices— blood glucose meters, blood pressure monitors and connected scales—as well as CGM devices to help empower better outcomes.</li>
<li>Seamless integration with Teladoc Health's 24/7 Care and primary care providers, as well as <a href="https://www.teladochealth.com/organizations/connected-care-partners">connected care partners</a> who can care for related conditions like joint pain and digestive health needs.</li>
</ul>

General

Teladoc Health Introduced Its Next Generation Cardiometabolic Health Program To Improve Population Health And Prevent The Progression Of Diabetes, Hypertension And Obesity

Shares of Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) have been under pressure since the fourth-quarter earnings release on Feb. 26.
JPMorgan analysts blamed the persistent underperformance of BetterHelp and "a more challenging operating backdrop complicated by renewed macroeconomic concerns.&#8221;
The Teladoc Health Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e4055351b9b00018beea6/lisa-gill">Analyst Lisa Gill</a> reaffirmed a Neutral rating, while reducing the price target from $13 to $11.
The Teladoc Health Thesis: The company is likely to generate Q1 revenues of $617.5 million, versus consensus of $619 million.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The adjusted EBITDA is likely to be $52.8 million, versus consensus of $53 million, she added.
The analyst projected full-year revenue estimate at $2.52 billion. That&#8217;s slightly higher than the consensus of $2,519 million.
The analyst also has a 2026 estimate of $2.56 billion, versus consensus of $2.558 billion.
Gill lowered the <a>adjusted EBITDA estimates for 2025 and 2026 from $311 million to $294 million and from $333 million to $314 million</a>, respectively.
"Our revenue estimates assume Integrated Care growth of +2% and +3% and we model BetterHelp down -7.7% and flat in FY25 and FY26, respectively," she wrote.
While the scale of Teladoc Health platform and the longer-term strategic direction are good, "there is more work to be done," Gill added.
Price Action: Shares of Teladoc Health had risen by 0.06% to $8.62 at the time of publication on Monday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43949618/cisco-and-nvidia-expand-ai-partnership-secure-us-government-authorization-for-cloud-security">Teladoc Health Partners With Eli Liily&#8217;s LillyDirect to Expand Access to Zepbound For Weight Loss</a></li>
</ul>
Photo courtesy of Teladoc
&nbsp;&nbsp;

Analyst Color

Tech

Teladoc Health Q1 Preview: Analyst Says Strategic Direction Is Good, But There's 'More Work To Be Done'

The rise of cash-pay GLP-1 prescriptions, fueled by programs like LillyDirect, is generating plenty of buzz—but JPMorgan analyst Lisa C. Gill isn't convinced this is a major shake-up for the <a href="https://www.benzinga.com/general/health-care">healthcare supply chain</a>. 
According to Gill, while Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) direct-to-consumer push is putting pressure on compounding pharmacies, it's not a volume shift that should worry pharmaceutical distributors.
LillyDirect's fulfillment model bypasses traditional distributors by shipping straight from Lilly's warehouses via partners like Amazon.com Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Pharmacy and Truepill.
Read Also: <a href="https://www.benzinga.com/25/03/44175948/alzheimers-drugs-from-eli-lilly-and-biogen-still-deemed-too-costly-for-nhs-funding">Alzheimer&#8217;s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding</a>
That means these sales aren't "lost" volume for distributors—they were never in their lane to begin with. Plus, GLP-1 distribution has never been a major profit driver for pharma distributors, so even if some volume moves from compounding pharmacies to LillyDirect, Gill sees minimal impact on their bottom lines.
<h2 class="wp-block-heading">The Numbers Tell The Story</h2>
LillyDirect's GLP-1 play is still a sliver of the market. Even assuming 5% of 2025's estimated 16.2 million Zepbound prescriptions run through LillyDirect, that's just 800,000 scripts &#8211; a drop in the 4.65 billion-prescription U.S. market bucket. 
Translation? This isn't a disruption; it's a strategic skirmish.
<h2 class="wp-block-heading">A Win For Teladoc?</h2>
One clear winner in this shake-up could be Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>). The company is <a href="https://www.benzinga.com/general/health-care/25/03/44170605/teladoc-health-partners-with-eli-liilys-lillydirect-to-expand-access-to-zepbound-for-weight-loss">integrating LillyDirect into its Chronic Care Weight Management program</a>, potentially boosting enrollments. With GLP-1 costs squeezing insurers, this partnership could make Teladoc's weight management offering more attractive to employers looking for coverage alternatives.
LillyDirect may be making waves, but for pharma distributors, it's business as usual. 
As Gill puts it, the GLP-1 cash-pay trend is more about pressuring compounding pharmacies than upending the broader supply chain. 
Investors eyeing big disruptions might want to look elsewhere.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/03/44182967/weight-loss-drugs-soar-while-global-obesity-rates-climb-to-hit-50-of-adults-by-2050-says-new-report">Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report</a></li>
</ul>
Image: Shutterstock

Biotech

Long Ideas

Trading Ideas

AMZN

Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan

Telemedicine operator Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) has entered a pharmacy integration agreement with Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) LillyDirect, a direct-to-consumer pharmacy partner, to streamline access to Zepbound (tirzepatide) for members of Teladoc's Comprehensive <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">Weight Care Program</a>.
Last year, Eli Lilly&nbsp;announced a&nbsp;new&nbsp;website allowing patients to get a prescription for weight loss through a telehealth provider,&nbsp;<a target="_blank" href="https://www.benzinga.com/top-stories/24/05/38798101/pfizer-follows-eli-lillys-footsteps-to-sell-medicines-directly-to-patients" rel="noreferrer noopener">marking an industry first</a>.
The collaboration aims to provide affordable and safe options for individuals without insurance coverage for GLP-1 medications <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44164208/teladoc-health-adds-glp-1-self-pay-option-to-comprehensive-weight-care" rel="noreferrer noopener">used for obesity treatment</a>.
Under the agreement, eligible Teladoc Health members prescribed Zepbound by their provider will have the medication delivered directly to their homes via LillyDirect's digital healthcare platform.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42970274/teladoc-shares-surge-as-amazon-partnership-fuels-push-for-consumer-centric-healthcare" rel="noreferrer noopener">Teladoc Stock Gains As Amazon Partnership Fuels Push for Consumer-Centric Healthcare</a>
Teladoc's Comprehensive Weight Care and Primary360 teams will have full visibility into each stage of the fulfillment process, including dispensing, shipping, delivery, and refills.
Beyond medication access, Teladoc's Comprehensive Weight Care Program offers a multi-disciplinary approach to obesity management. Members receive support from licensed clinicians with specialized training in obesity medicine, registered dietitians, and health coaches.
Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>)&nbsp;recently introduced&nbsp;NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44143391/novo-nordisk-boosts-wegovy-access-with-lower-pricing-and-home-delivery" rel="noreferrer noopener">cash-paying patients</a>.
In February, Teladoc reported fourth-quarter revenue&nbsp;of $640.5 million, down 3% year over year, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43989576/teladoc-health-reports-full-year-and-fourth-quarter-2024-results" rel="noreferrer noopener">consensus estimates</a>.
Price Action: TDOC stock is up 8.02% at $9.75 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44167381/target-hospitality-secures-five-year-lease-with-corecivic-for-dilley-facility-stock-gains" target="_blank" rel="noreferrer noopener">Target Hospitality Secures Five-Year Lease With CoreCivic For Dilley Facility, Stock Gains</a></li>
</ul>
Photo by Ciara Kimsey via Shutterstock

Large Cap

Contracts

Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC

Cylinder joins Teladoc Health's Connected Care Program to expand access to virtual digestive care

Carrum Health Selected by Teladoc Health as Centers of Excellence Partner

AI Influence on Medical Diagnostics Generating Billion Dollar Revenues While Growing Adoption Reduces Healthcare Costs

Teladoc Health Introduces Next Generation Cardiometabolic Health Program

Teladoc Health to Announce First Quarter 2025 Financial Results

Teladoc Health Acquires UpLift, Expanding Consumer Access to Mental Health Care Services Through Covered Benefits

Comments

Teladoc Health

Interés en corto

Teladoc Health (NYSE:TDOC) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL